HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial ...
NEW YORK, NY / ACCESS Newswire / August 11, 2025 / New to The Street proudly spotlights its esteemed client, NRx Pharmaceuticals, Inc. (NRXP), which today announced that the U.S. Food and Drug ...
STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
VT3989, a transcriptional enhanced associate domain autopalmitoylation inhibitor, targets the Hippo pathway in mesothelioma treatment. The FDA's fast track designation aims to expedite VT3989's ...
WILMINGTON, Del., Aug. 11, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced US Food and Drug Administration (FDA) has granted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results